Recent News

April 17, 2018 at 7:10 AM EDT

Summary Toggle Proteostasis Receives Endorsement from the Cystic Fibrosis Foundation's Therapeutic Development Network for the Study of the Company's Amplifier, PTI-428, in CF Subjects on Background Symdeko™ Therapy

Phase 2 Study of PTI-428 + Symdeko Planned to Initiate in 3Q'18; Study Intended to Expand Population of CF subjects in Phase 3 to Include Both Orkambi and Symdeko Standard of Care CAMBRIDGE, Mass. , April 17, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc.
April 4, 2018 at 6:00 AM EDT

Summary Toggle Proteostasis Therapeutics Receives FDA Fast Track Designation for Triple Combination Program in Patients with Cystic Fibrosis

CAMBRIDGE, Mass. , April 4, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein
March 20, 2018 at 7:59 PM EDT

Summary Toggle Proteostasis Therapeutics Announces Withdrawal of Equity Offering Due to Market Conditions

CAMBRIDGE, Mass. , March 20, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein
March 19, 2018 at 4:01 PM EDT

Summary Toggle Proteostasis Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass. , March 19, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein
March 14, 2018 at 5:29 PM EDT

Summary Toggle Proteostasis Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Business Update

14-day Study of PTI-801, Company’s Third Generation Corrector, in CF Patients on Background Orkambi ® Enrolling Ahead of Schedule; Results from All Three Cohorts Expected Q2'18 Company Announces Additional Study of PTI-428 in CF Subjects on Symdeko™ to Support Path to NDA, with Initial Data
March 14, 2018 at 4:30 PM EDT

Summary Toggle Proteostasis Therapeutics Announces FDA Grants Orphan Drug Designation for PTI-428 in Cystic Fibrosis

CAMBRIDGE, Mass. , March 14, 2018 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein
March 12, 2018 at 4:05 PM EDT

Summary Toggle Proteostasis Therapeutics Announces FDA Grants Breakthrough Therapy Designation for PTI-428 in Cystic Fibrosis

Designation granted for PTI-428 for the treatment of CF patients based on the results from a recent Phase 2, randomized, placebo controlled study CAMBRIDGE, Mass. , March 12, 2018 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated
March 7, 2018 at 7:00 AM EST

Summary Toggle Proteostasis Therapeutics to Present at the Cowen and Company 38th Annual Health Care Conference

CAMBRIDGE, Mass. , March 07, 2018 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein
February 8, 2018 at 7:00 AM EST

Summary Toggle Proteostasis Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference

CAMBRIDGE, Mass. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein
January 8, 2018 at 7:00 AM EST

Summary Toggle Proteostasis’ Proprietary Triple Combination Therapy Study Protocol Receives Endorsement and High Strategic Fit Score from the Largest Cystic Fibrosis Patient Advocacy Groups in the U.S. and Europe

Triple Combination of PTI-428, PTI-801 and PTI-808 Study to Initiate Dosing in CF Patients in 1H’18 CAMBRIDGE, Mass. , Jan. 08, 2018 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics , Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of